Postoperative Hypofractionated Intensity-modulated Radiation Therapy in Cervical Cancer
Condition(s) studied
Investigational drug(s) / intervention(s)
POHIM-RT: postoperative adjuvant IMRT with hypofractionation (2.5 Gy/fraction, 16 fractions, once a day)
Study summary
To investigate the acute toxicities, late toxicities, and treatment results when the early cervical cancer patients are treated by hypofractionated intensity-modulated radiotherapy (2.5 Gy X 16 fractions, once a day) after radical hysterectomy.
Eligibility
Primary outcome measure(s)
- acute toxicities according to CTCAE v4.0 — 3 months
evaluation of acute toxicities within 3months after radiotherapy according to CTCAE v4.0
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Samsung Medical Center | Seoul | South Korea |
More Samsung Medical Center trials in South Korea
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03239626 on ClinicalTrials.gov ↗ ← All trials in South Korea